NCT07401498Enrolling by invitation
Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).
A Multicenter Prospective Observational Study of the Incidence and Predictors of Complications Directly Related to Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
Systemic mediastinal lymph node dissection is a standard step in radical surgery for advanced non-small cell lung cancer (NSCLC). However, it does not carry the risks associated with certain procedures (chylothorax, recurrent nerve palsy, diaphragmatic relaxation, intrapleural hemorrhage, injury to other chest organs (esophagus, great vessels), etc.). Data on their incidence and predictors in routine practice are limited. Objective: To assess trends and characteristics of projects directly related to Lymph Node Dissection and to identify independent risk factors for their development.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 14 Aug 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Regional Clinical Oncology Dispensary
- Diseases
- Lung cancer
- NCT number
- NCT07401498
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 14 Aug 2025 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- "Wedge" surgery without any lymph node dissection.
- Nonemergency surgery; conversion is acceptable.
- Patients who cannot complete 30 days of observation (no contact, etc.) should be excluded prior to surgery.
Other illness
- Small cell lung cancer, benign and metastatic tumors.
Who the study is looking for
- Age ≥18 years.
- Clinical stage IA-IIIB NSCLC (TNM 8th edition), oncologically radical resection is planned: anatomical segmentectomy/lobectomy/bilobectomy/pneumonectomy (including sleeve resection).
- LND (systematic) is performed with mandatory inclusion of group 7 (subcarinal) lymph nodes.
- Signed informed consent from all study patients.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Regional Clinical Oncology Dispensary Coordinator of this site? Confirm its status | Ulyanovsk | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.